查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1667898

下呼吸道治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、藥物類別、給藥途徑、最終用戶、地區和競爭細分，2020-2030 年預測

Lower Respiratory Tract Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Drug Class, By Route of Administration, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球下呼吸道治療市場價值為 360.4 億美元，預計到 2030 年將達到 589.8 億美元，年複合成長率(CAGR) 為 8.53%。推動這一市場成長的關鍵因素包括肺炎、支氣管炎和慢性阻塞性肺病（COPD）等呼吸系統疾病的發生率上升。這些疾病在全球範圍內的負擔越來越重，特別是對於老年人和免疫功能低下者等弱勢群體，這推動了對有效治療方案的需求。此外，城市化、環境污染物的暴露以及許多地區的吸煙率較高進一步加劇了這些疾病的發病率，這反過來又推動了對治療急性和慢性呼吸道感染的治療方法的需求。醫療保健基礎設施的擴張，特別是在發展中地區，也提高了診斷和治療的可近性，促進了呼吸治療市場的持續成長。

市場概況
預測期 2026-2030
2024 年市場規模 360.4 億美元
2030 年市場規模 589.8 億美元
2025-2030 年複合年成長率 8.53%
成長最快的領域 醫院和診所
最大的市場 北美洲

主要市場促進因素：

主要市場挑戰：

主要市場趨勢：

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：COVID-19 對全球下呼吸道治療市場的影響

第 5 章：顧客之聲

第6章：全球下呼吸道治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病類型（氣喘、慢性阻塞性肺病、肺炎、結核病、支氣管炎、其他）
    • 依藥物類別（抗生素、非類固醇抗發炎藥、止咳藥、鼻減充血劑、其他）
    • 依給藥途徑（口服、腸胃外、其他）
    • 按最終使用者（醫院和診所、門診護理中心、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 7 章：亞太地區下呼吸道治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 8 章：歐洲下呼吸道治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 9 章：北美下呼吸道治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 10 章：南美洲下呼吸道治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲下呼吸道治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：市場動態

  • 驅動程式
  • 挑戰

第 13 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 14 章：全球下呼吸道治療市場：SWOT 分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章： 大環境分析

第 17 章：競爭格局

  • F. Hoffman - La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc

第 18 章：策略建議

第19章 關於出版商,免責事項

簡介目錄
Product Code: 19065

The Global Lower Respiratory Tract Therapeutics Market was valued at USD 36.04 billion in 2024 and is projected to reach USD 58.98 billion by 2030, registering a Compound Annual Growth Rate (CAGR) of 8.53%. This market growth is driven by key factors such as the rising prevalence of respiratory diseases like pneumonia, bronchitis, and chronic obstructive pulmonary disease (COPD). The increasing global burden of these conditions, particularly among vulnerable groups like the elderly and immunocompromised individuals, has fueled the demand for effective treatment options. Additionally, urbanization, exposure to environmental pollutants, and higher smoking rates in many regions are further aggravating the incidence of these diseases, which in turn drives the need for therapeutics to address both acute and chronic respiratory infections. The expansion of healthcare infrastructure, especially in developing regions, has also enhanced the accessibility of diagnoses and treatments, contributing to a growing market for respiratory therapeutics.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 36.04 Billion
Market Size 2030USD 58.98 Billion
CAGR 2025-20308.53%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Key Market Drivers:

Rising Prevalence of Respiratory Disorders The global healthcare landscape is seeing a notable rise in respiratory disorders, particularly lower respiratory tract conditions. Disorders such as chronic obstructive pulmonary disease (COPD), asthma, pneumonia, and bronchitis are becoming more widespread, leading to heightened demand for effective therapeutic solutions. Lower respiratory tract conditions, which significantly affect lung function and overall quality of life, are among the most prevalent and debilitating. These conditions are becoming increasingly common, driven by factors such as urbanization, pollution, tobacco use, and sedentary lifestyles, alongside an aging population more susceptible to respiratory health issues.

Key Market Challenges:

Competition from Generic Drugs The market for lower respiratory tract therapeutics faces considerable challenges from intense competition and the growing availability of generic drugs. As branded therapies become established, generic alternatives often enter the market, offering more cost-effective options for patients. This price competition places pressure on pharmaceutical companies, particularly those marketing patented treatments, as generics provide comparable therapeutic effects at a much lower cost. The widespread use of generic drugs plays a pivotal role in reducing healthcare costs, posing a challenge for branded drug manufacturers to retain market share.

Key Market Trends:

Shift Towards Targeted Therapies There is a significant trend toward the development of targeted therapies in the global lower respiratory tract therapeutics market. This shift is driven by advancements in molecular biology and a deeper understanding of disease mechanisms. Targeted therapies aim to address the root causes of diseases such as COPD and asthma, rather than just alleviating symptoms. For example, biologic agents like monoclonal antibodies are being developed to target specific inflammatory molecules such as interleukins, which are integral in diseases like asthma and COPD. These treatments offer enhanced precision by directly addressing the underlying mechanisms of disease.

Key Market Players:

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca Inc.
  • Johnson & Johnson
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Report Scope:

This report segments the Global Lower Respiratory Tract Therapeutics Market into the following categories, with detailed industry trends:

By Disease Type:

  • Asthma
  • COPD
  • Pneumonia
  • Tuberculosis
  • Bronchitis
  • Others

By Drug Class:

  • Antibiotics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Cough Suppressants
  • Nasal Decongestants
  • Others

By Route of Administration:

  • Oral
  • Parenteral
  • Others

By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

By Region:

  • North America (United States, Canada, Mexico)
  • Europe (France, United Kingdom, Italy, Germany, Spain)
  • Asia-Pacific (China, India, Japan, Australia, South Korea)
  • South America (Brazil, Argentina, Colombia)
  • Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape:

Company Profiles: This section provides a detailed analysis of the major companies operating in the Lower Respiratory Tract Therapeutics Market.

Available Customizations:

The Global Lower Respiratory Tract Therapeutics Market report offers customizations tailored to the specific needs of a company. The following customization options are available:

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Applications
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Lower Respiratory Tract Therapeutics Market

5. Voice of Customer

6. Global Lower Respiratory Tract Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type (Asthma, COPD, Pneumonia, Tuberculosis, Bronchitis, Others)
    • 6.2.2. By Drug Class (Antibiotics, Non-Steroidal Anti-Inflammatory Drugs, Cough Suppressants, Nasal Decongestants, Others)
    • 6.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 6.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centres, Others)
    • 6.2.5. By Region
    • 6.2.6. By Company (2024)
  • 6.3. Market Map

7. Asia Pacific Lower Respiratory Tract Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Drug Class
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Asia Pacific: Country Analysis
    • 7.3.1. China Lower Respiratory Tract Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Drug Class
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
    • 7.3.2. India Lower Respiratory Tract Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Drug Class
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
    • 7.3.3. Australia Lower Respiratory Tract Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Drug Class
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User
    • 7.3.4. Japan Lower Respiratory Tract Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Drug Class
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By End User
    • 7.3.5. South Korea Lower Respiratory Tract Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Drug Class
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By End User

8. Europe Lower Respiratory Tract Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Drug Class
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Lower Respiratory Tract Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Drug Class
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Lower Respiratory Tract Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Drug Class
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
    • 8.3.3. Spain Lower Respiratory Tract Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Drug Class
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Lower Respiratory Tract Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Drug Class
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End User
    • 8.3.5. United Kingdom Lower Respiratory Tract Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Drug Class
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End User

9. North America Lower Respiratory Tract Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Drug Class
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Lower Respiratory Tract Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Drug Class
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
    • 9.3.2. Mexico Lower Respiratory Tract Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Drug Class
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
    • 9.3.3. Canada Lower Respiratory Tract Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Drug Class
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User

10. South America Lower Respiratory Tract Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Drug Class
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Lower Respiratory Tract Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Drug Class
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End User
    • 10.3.2. Argentina Lower Respiratory Tract Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Drug Class
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End User
    • 10.3.3. Colombia Lower Respiratory Tract Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Drug Class
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End User

11. Middle East and Africa Lower Respiratory Tract Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Disease Type
    • 11.2.2. By Drug Class
    • 11.2.3. By Route of Administration
    • 11.2.4. By End User
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Lower Respiratory Tract Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Disease Type
        • 11.3.1.2.2. By Drug Class
        • 11.3.1.2.3. By Route of Administration
        • 11.3.1.2.4. By End User
    • 11.3.2. Saudi Arabia Lower Respiratory Tract Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Disease Type
        • 11.3.2.2.2. By Drug Class
        • 11.3.2.2.3. By Route of Administration
        • 11.3.2.2.4. By End User
    • 11.3.3. UAE Lower Respiratory Tract Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Disease Type
        • 11.3.3.2.2. By Drug Class
        • 11.3.3.2.3. By Route of Administration
        • 11.3.3.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. Global Lower Respiratory Tract Therapeutics Market: SWOT Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. PESTLE Analysis

17. Competitive Landscape

  • 17.1. F. Hoffman - La Roche Ltd
    • 17.1.1. Business Overview
    • 17.1.2. Company Snapshot
    • 17.1.3. Products & Services
    • 17.1.4. Financials (In case of listed companies)
    • 17.1.5. Recent Developments
  • 17.2. Teva Pharmaceutical Industries Ltd.
  • 17.3. Sanofi S.A
  • 17.4. Pfizer Inc.
  • 17.5. GSK plc
  • 17.6. Novartis AG
  • 17.7. AstraZeneca
  • 17.8. Johnson & Johnson
  • 17.9. Sun Pharmaceutical Industries Ltd.
  • 17.10. Merck & Co., Inc

18. Strategic Recommendations

19. About Us & Disclaimer